Circulating CD4+ T cells that produce IL4 or IL17 when stimulated by melan-A but not by NY-ESO-1 have negative impacts on survival of patients with stage IV melanoma.
Zelba H, Weide B, Martens A, Derhovanessian E, Bailur JK, Kyzirakos C, Pflugfelder A, Eigentler TK, Di Giacomo AM, Maio M, Aarntzen EH, de Vries J, Sucker A, Schadendorf D, Büttner P, Garbe C, Pawelec G.
Zelba H, et al. Among authors: derhovanessian e.
Clin Cancer Res. 2014 Aug 15;20(16):4390-9. doi: 10.1158/1078-0432.CCR-14-1015. Epub 2014 Jun 17.
Clin Cancer Res. 2014.
PMID: 24938524